View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings assigns a Ba2 rating to Coty's new senior secured note...

Moody's Ratings (Moody's) assigned a Ba2 rating to Coty, Inc.'s ("Coty") new senior secured notes. All other ratings including the company's Ba2 Corporate Family Rating (CFR), Ba2-PD Probability of Default Rating (PDR), Ba2 senior secured revolver and notes ratings, B1 senior unsecured note ratings ...

 PRESS RELEASE

Coty Inc. to Offer Senior Secured Notes

NEW YORK--(BUSINESS WIRE)-- Regulatory News: Coty Inc. (NYSE: COTY) (Paris: COTY)(“Coty”), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, today announced that it, together with its wholly-owned subsidiaries, HFC Prestige Products, Inc. and HFC Prestige International U.S. LLC (the “Co-Issuers” and collectively with Coty, the “Issuers”), launched an offering of €500 million aggregate principal amount of senior secured notes (the “Notes”), subject to market and customary conditions. The interest rates and ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 18, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: May 15, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Vaccinex Reports First Quarter 2024 Financial Results and Provides Cor...

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced financial results for the first quarter ended March 31, 2024, and provided a cor...

 PRESS RELEASE

PubMatic to Participate at Upcoming Investor Summit

PubMatic to Participate at Upcoming Investor Summit NO-HEADQUARTERS/REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- PubMatic, Inc. (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced that members of its management team are scheduled to participate at an upcoming investor summit. Details for the event are as follows: Evercore ISI 3rd Annual Nothing But Net Internet Summit in New York on Wednesday May 29, 2024. About PubMatic PubMatic (Nasdaq: PUBM) is an independent technology company maximizing custome...

 PRESS RELEASE

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome community REDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign aims to raise awareness...

David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics to Participate in Upcoming Investor Conferences ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside cha...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 11, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TSCO TRACTOR SUPPLY COMPANY
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
QCOM QUALCOMM INC
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
MU MICRON TECHNOLOGY INC.
LTC LTC PROPERTIES INC.
LOW LOWE'S COMPANIES INC.
JCOM J2 GLOBAL INC.
INTC INTEL CORPORATION
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
35G GENPACT LIMITED
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
CHUY CHUY'S HOLDINGS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
OKTA OKTA INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
PRPL PURPLE INNOVATION
LEGH LEGACY HOUSING CORP
CRNC CERENCE
SMCI SUPER MICRO COMPUTER
U INC.
PLTR UNITY SOFTWARE
VOR PALANTIR TECHNOLOGIES
PLTK VOR BIOPHARMA
SNOW PLAYTIKA HOLDING
RBLX SNOWFLAKE INC. CLASS A
GHLD ROBLOX
MRVL GUILD HOLDINGS
STX MARVELL TECHNOLOGY INC
ALIT SEAGATE TECHNOLOGY HLDGS PLC
UWMC FOLEY TRASIMENE ACQUISITION CORP
ATXS UWM HLDGS CORP
CCSI ASTRIA THERAPEUTICS INC
GFS CONSENSUS CLOUD SOLUTIONS INC
TYRA GLOBALFOUNDRIES INC
SOUN TYRA BIOSCIENCES INC
GETY SOUNDHOUND AI INC
GTBIF GETTY IMAGES HOLDINGS INC
SKLZ GREEN THUMB INDUSTRIES INC.
DNTH SKILLZ INC
DIANTHUS THERAPEUTICS INC
 PRESS RELEASE

Soleno Therapeutics Provides Corporate Update and Reports First Quarte...

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public of...

 PRESS RELEASE

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 ...

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent cor...

 PRESS RELEASE

Oxbridge Re Holdings Limited Reports First Quarter 2024 Results

Oxbridge Re Holdings Limited Reports First Quarter 2024 Results GRAND CAYMAN, Cayman Islands, May 09, 2024 (GLOBE NEWSWIRE) -- (), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities and reinsurance solutions primarily to property and casualty insurers, today reported its results for the three months ended March 31, 2024. “We were pleased with our core operational performance in the first quarter of 2024 in our Web-3 and reinsurance tokenization business," co...

Michael Pachter ... (+2)
  • Michael Pachter
  • Nick McKay
Michael Pachter ... (+2)
  • Michael Pachter
  • Nick McKay
 PRESS RELEASE

Perma-Fix Reports Financial Results and Provides Business Update for t...

Perma-Fix Reports Financial Results and Provides Business Update for the First Quarter of 2024 ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2024. Mark Duff, President and CEO of the Company, commented, “As previously disclosed, our financial performance in the first quarter of 2024 was impacted by a few temporary headwinds. However, we have seen steady improvement heading into the second quarter and anticipate a ...

 PRESS RELEASE

Design Therapeutics Announces First Quarter 2024 Financial Results and...

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington’s Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinica...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch